Patent ID: 9694005
Date: 2017-07-04
CPC Classifications: A61K,A61P,C07D,C07J

Claim:
1. A method of treating cancer comprising administering an effective amount of a compound selected from the group consisting of 3β-(1H-imidazol-1-yl)-17-(1H-benzimidazol-1-yl)androsta-5,16-diene (VNPP433-3β (A1)), 3β-(pyridine-4-ylmethoxy)-17-(1H-benzimidazol-1-yl)androsta-5,16-diene (VNPP414(A16)), 6-(3-benzimidazolylphenyl)naphthalen-2-ol (VNPP372/2(Na1)), and N-(3-benzimidazolylphenyl)[(4-methoxyphenyl) sulphonyl]amine (VNPP431(SulAmd2)) to a patient in need thereof, wherein said cancer is prostate cancer or castration resistant human prostate cancer.